MeiraGTx Holdings Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 389

Employees

  • Stock Symbol
  • MGTX

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $6.60
  • (As of Thursday Closing)

MeiraGTx Holdings General Information

Description

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Contact Information

Formerly Known As
Kadmon Gene Therapy
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 450 East 29th Street
  • 14th Floor
  • New York, NY 10016
  • United States
+1 (646)
Primary Industry
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 450 East 29th Street
  • 14th Floor
  • New York, NY 10016
  • United States
+1 (646)

MeiraGTx Holdings Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MeiraGTx Holdings Stock Performance

As of 13-Feb-2025, MeiraGTx Holdings’s stock price is $6.60. Its current market cap is $516M with 78.2M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.60 $6.44 $3.85 - $7.37 $516M 78.2M 272K -$1.20

MeiraGTx Holdings Financials Summary

As of 30-Sep-2024, MeiraGTx Holdings has a trailing 12-month revenue of $13.9M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 309,449 473,279 293,327 936,118
Revenue 13,929 14,017 15,920 37,701
EBITDA (64,866) (59,330) (116,843) (70,885)
Net Income (88,177) (84,027) (129,615) (79,561)
Total Assets 299,488 326,744 318,237 320,164
Total Debt 86,735 89,264 92,248 23,733
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MeiraGTx Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MeiraGTx Holdings‘s full profile, request access.

Request a free trial

MeiraGTx Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervo
Biotechnology
New York, NY
389 As of 2024

New York, NY
 

Planegg, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MeiraGTx Holdings Competitors (6)

One of MeiraGTx Holdings’s 6 competitors is Axsome Therapeutics, a Corporation company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axsome Therapeutics Corporation New York, NY
MediGene Formerly VC-backed Planegg, Germany
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Arcturus Therapeutics Formerly VC-backed San Diego, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
To view MeiraGTx Holdings’s complete competitors history, request access »

MeiraGTx Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MeiraGTx Holdings Investments & Acquisitions (5)

MeiraGTx Holdings’s most recent deal was a Merger/Acquisition with Bullseye Therapeutics for . The deal was made on 04-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bullseye Therapeutics 04-Oct-2021 Merger/Acquisition Drug Discovery
Visiogene (IP Rights Relating to Ocular Gene Therapy in Massachusetts, United States) 04-Jan-2021 Corporate Asset Purchase Buildings and Property
Emrys Bio 09-Apr-2020 Merger/Acquisition Biotechnology
Arthrogen 17-Oct-2019 Merger/Acquisition Biotechnology
Vector Neurosciences 05-Oct-2018 Merger/Acquisition Biotechnology
To view MeiraGTx Holdings’s complete investments and acquisitions history, request access »

MeiraGTx Holdings ESG

Risk Overview

Risk Rating

Updated January, 30, 2024

28.94 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view MeiraGTx Holdings’s complete esg history, request access »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Athena Brands London, United Kingdom 2015

MeiraGTx Holdings FAQs

  • When was MeiraGTx Holdings founded?

    MeiraGTx Holdings was founded in 2015.

  • Where is MeiraGTx Holdings headquartered?

    MeiraGTx Holdings is headquartered in New York, NY.

  • What is the size of MeiraGTx Holdings?

    MeiraGTx Holdings has 389 total employees.

  • What industry is MeiraGTx Holdings in?

    MeiraGTx Holdings’s primary industry is Biotechnology.

  • Is MeiraGTx Holdings a private or public company?

    MeiraGTx Holdings is a Public company.

  • What is MeiraGTx Holdings’s stock symbol?

    The ticker symbol for MeiraGTx Holdings is MGTX.

  • What is the current stock price of MeiraGTx Holdings?

    As of 13-Feb-2025 the stock price of MeiraGTx Holdings is $6.60.

  • What is the current market cap of MeiraGTx Holdings?

    The current market capitalization of MeiraGTx Holdings is $516M.

  • What is MeiraGTx Holdings’s current revenue?

    The trailing twelve month revenue for MeiraGTx Holdings is $13.9M.

  • Who are MeiraGTx Holdings’s competitors?

    Axsome Therapeutics, MediGene, Immunocore Holdings, Arcturus Therapeutics, and Inovio Pharmaceuticals are some of the 6 competitors of MeiraGTx Holdings.

  • What is MeiraGTx Holdings’s annual earnings per share (EPS)?

    MeiraGTx Holdings’s EPS for 12 months was -$1.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »